To provide some context to the broader bio-tech market I'll...

To provide some context to the broader bio-tech market I'll share some research by @buysidebio on X detailing the worst biotech bear market on record:

The Sub 200M market cap bracket has seen the largest decline since 2/8/21, with an average drop of -86% and a median of -93%.Companies in the 200M-500M range lost over half their value since the peak, with a median decline of -79%.

Larger companies, specifically those with a market cap of 8B+, showed resilience with an average return of 11% year-to-date and an increase of 9% since the 2/8/21 peak.Across all market cap buckets, there's been an average decline of -43% since 2/8/21, with a median drop of -54%.

The number of companies with a negative enterprise value (EV) surged from 6 on 2/8/21 to 221 (35%) currently. Remarkably, 71% of these negative EV companies have less than 2 years of cash.

20% of biotech companies previously bucketed back on 2/8/21 are now valued at <50M. $XBI